NEW YORK, NY / ACCESSWIRE / June 11, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?prid=16809&wire=1
Lead Plaintiff Deadline: June 18, 2021
Class Period: June 15, 2020 - April 4, 2021
Allegations against ACAD include that: (i) the materials submitted in support of the pimavanserin supplemental new drug application (sDNA) contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the Food and Drug Administration Agency was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Emergent Biosolutions Inc. (NYSE:EBS)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?prid=16809&wire=1
Lead Plaintiff Deadline: June 18, 2021
Class Period: April 24, 2020 - April 16, 2021
Allegations against EBS include that: (i) Emergent's Baltimore plant had a history of manufacturing issues increasing the likelihood for massive contaminations; (ii) these longstanding contamination risks and quality control issues at Emergent's facility led to a string of FDA citations; (iii) the Company previously had to discard the equivalent of millions of doses of COVID-19 vaccines after workers at the Baltimore plant deviated from manufacturing standards; and (iv) as a result of the foregoing, Defendants' public statements about Emergent's ability and capacity to mass manufacture multiple COVID-19 vaccines at its Baltimore manufacturing site were materially false and/or misleading and/or lacked a reasonable basis.
PureCycle Technologies, Inc. (NASDAQ:PCT)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/purecycle-technologies-inc-loss-submission-form?prid=16809&wire=1
Lead Plaintiff Deadline: July 12, 2021
Class Period: November 16, 2020 - May 5, 2021
Allegations against PCT include that: (i) the technology PureCycle licensed from Procter & Gamble is not proven and presents serious issues even at lab scale; (ii) the challenges posed by the availability and competition for the raw materials necessary to commercialize the licensed technology are significant; (iii) PureCycle's financial projections are baseless; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong